MedTrace Logo

A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia

NCT03806556 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2021-09-20

Study results available
· View outcomes & findings →

Summary

This study evaluates the use of tranexamic acid (TXA) in addition to standard therapy in children receiving chemotherapy or blood and/or marrow transplantation to decrease the risk of bleeding. Half of participants will receive tranexamic acid and half of participants will receive placebo.

Conditions

  • Pediatric Cancer
  • Thrombocytopenia
  • Hemostatic Disorder
  • Coagulation Defect; Acquired

Interventions

DRUG

Tranexamic Acid

IV medication administered after patient meets inclusion/exclusion criteria

DRUG

Normal saline

IV medication administered after patient meets inclusion/exclusion criteria

Sponsors & Collaborators

  • Meghan McCormick

    lead OTHER

Principal Investigators

  • Meghan McCormick, MD · UPMC Childrens Hospital of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-22
Primary Completion
2020-08-25
Completion
2020-08-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03806556 on ClinicalTrials.gov